Form 8K current report
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
__________________________
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of
report (Date of earliest event reported) September
15, 2006
Nephros,
Inc.
(Exact
Name of Registrant as Specified in Charter)
Commission
File Number: 001-32288
|
Delaware
|
|
13-3971809
|
|
(State
or other Jurisdiction of
Incorporation)
|
|
(I.R.S.
Employer Identification No.)
|
3960
Broadway, New York, New York 10032
(Address
of Principal Executive Offices)
(Zip
Code)
(212)
781-5113
(Registrant’s
telephone number, including area code)
Not
Applicable
(Former
name or former address, if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
r
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
r
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
r
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
r
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
5.02. Departure of Directors or Principle Officers; Election of Directors;
Appointment of Principal Officers.
On
September 15, 2006, the Board of Directors of Nephros, Inc. (the “Company”)
appointed Judy S. Slotkin as a director of the Company to fill a newly created
vacancy on the Board. There was no arrangement or understanding pursuant to
which Ms. Slotkin was elected as a director. The Company was not and is not
a
party to any transaction during the last two years or any proposed transactions
in which Ms. Slotkin had or is to have a direct or indirect material interest.
Ms. Slotkin has been appointed to serve on the Board’s Audit
Committee.
Ms.
Slotkin was Co-Head Finance Committee of the Modern Africa Fund, a $120 million
private equity fund, from 1998-2003. Prior to that, Ms. Slotkin held various
positions in Citigroup over 16 years, most recently serving as Managing Director
(Department Head) in the Corporate Finance Division of Citigroup (Citibank
Investment Bank) where she was responsible for various businesses and first
head
of the group’s Capital Markets Desk. Ms. Slotkin is a director of Siga
Technologies, Inc. Ms. Slotkin also serves on the Board of Trinity School,
New
York, New York and is a founding member of the Food Allergy Initiative, New
York, New York.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Date:
September 21, 2006
NEPHROS,
INC.
By:
/s/
Mark W.
Lerner
Mark
W. Lerner
Chief
Financial Officer
(Principal
Financial and Accounting Officer)